NCT00002746View on ClinicalTrials.gov

Interleukin-2 in Treating Patients With Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 1996

Primary Completion Date

April 30, 2004

Study Completion Date

April 30, 2004

Conditions
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Interventions
BIOLOGICAL

aldesleukin

Trial Locations (1)

98195-6043

University of Washington Medical Center, Seattle

All Listed Sponsors
lead

University of Washington

OTHER

NCT00002746 - Interleukin-2 in Treating Patients With Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter